Active, not recruitingPhase 1NCT03740334
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Andrew E Place, MD, PhDDana-Farber Cancer Institute
- Intervention
- Ribociclib(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 1-30 years · All sexes
- Timeline
- 2019 – 2026
Study locations (12)
- Children's Hospital Colorado, Aurora, Colorado, United States
- Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Texas Children's Hospital, Houston, Texas, United States
- Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Collaborators
Novartis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03740334 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University